Unité de Chirurgie, Département des Sciences Cliniques des Animaux de Compagnie, Ecole Nationale Vétérinaire de Toulouse, 23 Chemin des Capelles, BP 87614, 31076 Toulouse Cedex 3, France.
Vet Rec. 2011 Jun 11;168(23):617. doi: 10.1136/vr.d1456. Epub 2011 Jun 3.
Thirty-nine client-owned dogs with osteoarthritis were treated with 5 mg/kg firocoxib administered orally, once a day for 52 weeks. Veterinary examinations were performed on approximately days 0, 15, 90, 180, 270 and 360. Twenty-five dogs completed the study. The withdrawal rate associated with gastrointestinal side effects was low (5.1 per cent of dogs). Based on the owners' assessment, 82 per cent of the dogs had improved at day 15, 84 per cent of the 32 remaining dogs had improved at day 90, and 96 per cent of the 25 dogs that completed the trial had improved at day 360. During this trial, 12 (48 per cent) of the 25 remaining dogs showed an improvement in their lameness from day 90 to day 360 (P<0.05).
39 只患有骨关节炎的犬只接受了 5 毫克/千克的非甾体抗炎药（FIROCoxib）口服治疗，每天一次，持续 52 周。兽医在大约第 0、15、90、180、270 和 360 天进行了检查。25 只狗完成了研究。与胃肠道副作用相关的停药率较低（5.1%的狗）。根据主人的评估，82%的狗在第 15 天有所改善，32 只剩余狗中的 84%在第 90 天有所改善，25 只完成试验的狗中有 96%在第 360 天有所改善。在这项试验中，25 只剩余狗中有 12 只（48%）从第 90 天到第 360 天的跛行状况有所改善（P<0.05）。
